Suppr超能文献

纤溶药物在引流胸腔内感染中的应用。

Utility of fibrinolytic agents for draining intrapleural infections.

作者信息

Bouros D, Schiza S, Siafakas N

机构信息

Department of Pneumonology, Medical School University of Crete, University Hospital, Heraklion, Greece.

出版信息

Semin Respir Infect. 1999 Mar;14(1):39-47.

Abstract

Multiple studies have shown that the intrapleural instillation of fibrinolytic agents provides an effective and safe mode of treatment for complicated parapneumonic effusions and empyemas that decrease the need for surgical interventions. Although most investigators use streptokinase and urokinase, the technique of instillation is not standardized. The usual dose of streptokinase is 250,000 IU, but doses range from 50,000 to 220,000 IU for urokinase. Reported success rates range from 38% to 100%, but outcomes depend on the stage of progression of the parapneumonic effusion when fibrinolytics are employed. Fibrinolytics are more effective in complicated parapneumonic effusions than in established empyemas. Although complications of fibrinolytic therapy rarely occur, they result most often from allergic reactions to streptokinase. Urokinase is safer but more expensive. More randomized, comparative, controlled studies are needed to further define the most effective mode of fibrinolytic therapy for subgroups of patients with pleural infection.

摘要

多项研究表明,胸膜腔内注入纤溶药物为复杂性肺炎旁胸腔积液和脓胸提供了一种有效且安全的治疗方式,可减少手术干预的需求。尽管大多数研究者使用链激酶和尿激酶,但注入技术并不规范。链激酶的常用剂量为250,000国际单位,而尿激酶的剂量范围为50,000至220,000国际单位。报道的成功率在38%至100%之间,但结果取决于使用纤溶药物时肺炎旁胸腔积液的进展阶段。纤溶药物在复杂性肺炎旁胸腔积液中比在已形成的脓胸中更有效。尽管纤溶治疗的并发症很少发生,但最常见的是由对链激酶的过敏反应引起的。尿激酶更安全但更昂贵。需要更多随机、比较、对照研究来进一步确定针对胸膜感染患者亚组的最有效纤溶治疗方式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验